Clinical outcomes with alpelisib (ALP) plus fulvestrant (FUL) after prior treatment (tx) with FUL in patients (pts) with advanced breast cancer (ABC): A real-world (RW) analysis.

被引：0
|
作者：
O'Shaughnessy, Joyce
Woeckel, Achim
Pistilli, Barbara
Hegg, Roberto
Vahdat, Linda T.
Vuina, Dragica
Asad, Zvk Parisa
Smith, Timothy W.
Kim, Julia
Krop, Ian
机构：
[1] Baylor Univ Med Ctr, Texas Oncol, US Oncol Network, Dallas, TX USA
[2] Univ Wurzburg, Wurzburg, Germany
[3] Inst Macerata, Macerata, Italy
[4] Univ Sao Paulo, Sao Paulo, SP, Brazil
[5] Dartmouth Canc Ctr, Lebanon, NH USA
[6] Novartis Oncol, Zagreb, Croatia
[7] Novartis Oncol, Basel, Switzerland
[8] Novartis Pharmaceut, E Hanover, NJ USA
[9] Genesis Res, Hoboken, NY USA
[10] Dana Farber Canc Inst, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1055
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Real-world features and outcomes of young advanced breast cancer (ABC) patients (pts) from RegistEM (GEICAM/2014-03) study
    Lopez-Tarruella, Sara
    Guerrero, Angel
    Alvarez, Isabel
    Novoa, Silvia Antolin
    Tibau, Ariadna
    Cruz, Josefina
    Rodriguez, Cesar A.
    Martinez, Purificacion
    Chacon, J. Ignacio
    Hernandez, Maria
    Margeli, Mireia
    Adrover, Encarna
    Falo, Catalina
    Gonzalez, Iria
    Rodriguez-Lescure, Alvaro
    Marin, Maria
    Gomez, Cesar
    de la Haba-Rodriguez, Juan
    Illaramendi, J. Jose
    Andres, Raquel
    Blasco, Andrea
    Escudero, Ma Jose
    Bezares, Susana
    Rojo, Federico
    CANCER RESEARCH, 2024, 84 (09)
  • [22] Real-world (RW) treatment (Tx) patterns and clinical outcomes in patients (pts) with metastatic urothelial carcinoma (mUC): Results of a nationwide, longitudinal, retrospective study in Hungary
    Maraz, A. C.
    Nagy, B.
    Macher, T.
    Jesko, J.
    Tischler, E.
    Csongvai, C.
    Kearney, M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1341 - S1341
  • [23] Palbociclib-fulvestrant (PALBO-FUL) and everolimus -exemestane (EVE-EXE) for second line hormonal treatment (HT) of metastatic breast cancer (MBC) with lobular histology: A propensity score matched analysis of a multicenter 'real-world' patients (pts) series
    Orlandi, A.
    Iattoni, E.
    Pizzuti, L.
    Fabbri, M. A.
    Botticelli, A.
    Di Dio, C.
    Palazzo, A.
    Garufi, G.
    Indellicati, G.
    Alesini, D.
    Carbognin, L.
    Paris, I.
    Vaccaro, A.
    Moscetti, L.
    Cassano, A.
    Vici, P.
    Giannarelli, D.
    Marchetti, P.
    Bria, E.
    Tortora, G.
    ANNALS OF ONCOLOGY, 2019, 30
  • [24] Association between post-treatment (tx) alpha-fetoprotein (AFP) reduction and outcomes in real-world (rw) US patients (pts) with advanced HCC (aHCC).
    Wang, Xiaoliang
    Magee, Kelly
    Gossai, Anala
    Parrinello, Christina M.
    Miksad, Rebecca A.
    Kim, Richard D.
    Abou-Alfa, Ghassan K.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [25] Overall survival (os) results from SOLAR-1, a phase III study of alpelisib (ALP) plus fulvestrant (FUL) for hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2e) advanced breast cancer (ABC)
    Andre, F.
    Ciruelos, E. M.
    Juric, D.
    Loibl, S.
    Campone, M.
    Mayer, I.
    Rubovszky, G.
    Yamashita, T.
    Kaufman, B.
    Lu, Y-S.
    Inoue, K.
    Papai, Z.
    Takahashi, M.
    Ghaznawi, F.
    Mills, D.
    Kaper, M.
    Miller, M.
    Conte, P. F.
    Iwata, H.
    Rugo, H. S.
    ANNALS OF ONCOLOGY, 2020, 31 : S1150 - S1151
  • [26] Real-world (RW) elacestrant use patterns and therapeutic outcomes in patients (pts) with hormone receptor-positive (HR+)/HER2-negative advanced breast cancer (aBC)
    Lloyd, Maxwell Roger
    Ali, Azka
    Weipert, Caroline M.
    Solomon, Sheila R.
    Saha, Jayati
    Lipsyc-Sharf, Marla
    Hamilton, Erika P.
    Kalinsky, Kevin
    Bardia, Aditya
    Zhang, Nicole
    Wander, Seth Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [27] Metformin (MF) in the prevention of hyperglycemia (HG) in patients (pts) with PIK3CA-mutated, hormone receptor (HR) [+]/HER2[-] advanced breast cancer (ABC) treated with alpelisib (ALP) plus fulvestrant (F): METALLICA
    Llombart Cussac, A.
    Perez-Garcia, J. M.
    Blanch, S.
    Tolosa, P.
    Ruiz Borrego, M.
    Gion Cortes, M.
    Fernadez, A.
    Urruticoechea, A.
    Galve, E.
    Cueva Banuelos, J. F.
    Ponce, J.
    Alonso, J. L.
    Capelan, M.
    Martinez, E.
    Bermejo De Las Heras, B.
    Rojas, B.
    Martos, T.
    Lopez, A.
    Gomez-Peralta, F.
    Cortes, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S77 - S77
  • [28] Real-world (RW) characteristics, treatment (tx) patterns, and overall survival (OS) in US patients (pts) with metastatic breast cancer (mBC) and CNS metastases (CNS mets)
    Shewade, Ashwini
    Hsieh, Angela Fu-Chi
    Mani, Aruna
    Al-Sakaff, Nedal Jaffer Abdulla
    Sanglier, Thibaut
    Taylor, Michael Dennis
    Heinzmann, Dominik
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [29] Real-world clinical outcomes in patients with local/regional HER2-low breast cancer: An NCDB analysis.
    Jiang, Changchuan
    Perimbeti, Stuthi
    Deng, Lei
    Wang, Qian
    Gandhi, Shipra
    Shapiro, Charles L.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [30] Real-World Treatment Patterns and Outcomes in Patients With Advanced NSCLC Treated After Prior Chemotherapy and Immunotherapy
    Haggstrom, D.
    Mhatre, S. K.
    Chen, F.
    Gao, R.
    Carroll, C.
    Patel, R.
    Park, J.
    Descoteaux, A.
    Stokes, M.
    Daniel, D.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S409 - S409
12345